EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Filippo Pietrantonio iD, Lisa Salvatore iD, Taito Esaki iD, Dominik Paul Modest iD, David Paez Lopez-Bravo, Julien Taieb iD, Michalis V Karamouzis iD, Erika Ruiz-Garcia iD, Tae Won Kim iD, Yasutoshi Kuboki iD, Fausto Meriggi, David Cunningham iD und 6 weitere

Journal of Clinical Oncology · 2025-07 · 43 (19) · 2147-2154

DOI: 10.1200/jco-24-02026 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-07. Verfasst von Filippo Pietrantonio und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)Antineoplastic Combined Chemotherapy ProtocolsHumansPanitumumabMaleFemaleMiddle AgedAgedAdultPyrimidinesProgression-Free SurvivalMutationAged, 80 and overThymineSulfonamidesPhenylurea CompoundsPiperazinesPyridines

Substanzen

PanitumumabProto-Oncogene Proteins p21(ras)KRAS protein, humansotorasibPyrimidinesThymineSulfonamidesPhenylurea CompoundsPiperazinesPyridines

Autor:innen und Institutionen

  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Oncologia Medica, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Medicine Department of Hematology, Oncology and Tumor Immunology, Charité - Universitaetsmedizin Berlin, Berlin, Germany.
  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

ORCID-Profile: Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, Julien Taieb, Michalis V Karamouzis, Erika Ruiz-Garcia, Tae Won Kim, Yasutoshi Kuboki, David Cunningham, Kun-Huei Yeh, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih

Zitieren

APA

Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K. H., Chan, E., Chao, J., Tran, Q., Cremolini, C., & Fakih, M. (2025). Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology, 43(19), 2147-2154. https://doi.org/10.1200/jco-24-02026

Vancouver

Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. Journal of Clinical Oncology. 2025;43(19):2147-2154. doi:10.1200/jco-24-02026

BibTeX
@article{Pietrantonio2025,
  author = {Pietrantonio, Filippo and Salvatore, Lisa and Esaki, Taito and Modest, Dominik Paul and Lopez-Bravo, David Paez and Taieb, Julien and Karamouzis, Michalis V and Ruiz-Garcia, Erika and Kim, Tae Won and Kuboki, Yasutoshi and Meriggi, Fausto and Cunningham, David and Yeh, Kun-Huei and Chan, Emily and Chao, Joseph and Tran, Qui and Cremolini, Chiara and Fakih, Marwan},
  title = {Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {19},
  pages = {2147--2154},
  doi = {10.1200/jco-24-02026}
}
Kostenlos starten →